EU, Nigeria sign €18m deal to boost vaccine production

The agreement was signed by Jutta Urpilainen, European Commissioner for International Partnerships, and Didi Walson-Jack, Permanent Secretary of Nigeria’s Federal Ministry of Education

The European Union and Nigeria have signed an €18 million agreement to enhance research and development in Nigeria, aligning with the country’s strategy to advance its pharmaceutical sector and boost local production of vaccines and medical technologies.

The agreement was signed by Jutta Urpilainen, European Commissioner for International Partnerships, and Didi Walson-Jack, Permanent Secretary of Nigeria’s Federal Ministry of Education, at the EU Global Gateway High-Level event on education in Brussels on Thursday.

Modestu Chukwulaka, the EU’s Head of Communication, stated on Friday that this partnership highlights the EU’s strong commitment to promoting educational and health equity.

Commissioner Urpilainen emphasized, “Economic growth depends on a well-educated, skilled workforce and robust healthcare systems. Thus, investing in strengthening education and health systems worldwide is a key component of the EU’s Global Gateway strategy.

“Our investments in quality education, research, and training aim to empower future generations by equipping them with the knowledge, skills, and competencies necessary to confront global challenges and foster prosperity.”

The European funding, allocated under the Team Europe Initiative on manufacturing and access to vaccines, medicines, and health technologies in Africa, will provide support for enhancing various facets of Nigeria’s pharmaceutical sector.

This support included skills development through education and training, research and development (including advancements in artificial intelligence and nanotechnology), digitalization of essential ecosystem dimensions, the establishment of a centralized system for forecasting, procurement, and distribution of quality medical products, as well as trade, investment, and customs facilitation.

Exit mobile version